Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease'. The following are the other relevant details related to the trial:
Therapeutic Area: Cardiology
Trial Centre(s):
Changi General Hospital
National Heart Centre
National University Hospital
Singapore General Hospital
Tan Tock Seng Hospital
Trial Status: Ongoing, Recruiting
Principal Investigator(s):
Dr Troy Puar Hai Kiat
Dr...